Ochsner Innovation Center enters into digital health partnership

Ochsner Health System's innovationOchsner (iO), its innovation lab and accelerator, is partnering with Evidation Health, a company launched by GE Ventures and Stanford Health Care.

Through the partnership, the New Orleans-based organizations will conduct clinical studies to determine the real-world impact of digital solutions on the health of patients and the cost of care. The affiliation brings Ochsner Health System’s medical expertise and diverse patient population together with iO’s digital health capabilities and Evidation Health’s technology platform, data analytics engine and health outcomes research capabilities to enable more efficient testing of digital health solution impact.

iO is pioneering digital health solutions, enabling Ochsner Health System to adopt new technologies and integrate them into its patient care model.

Evidation Health’s technology platform and analytics capabilities enable integration of medical, behavioral and contextual data to quantify clinical and economic benefit. The company has the ability to link patient behavioral data from over 100 apps and devices with clinical data to understand and predict the impact of behaviors on health outcomes.

“Our focus in digital health is to demonstrate real-world health outcomes for patients, payers and provider systems, especially in conditions where patient behavior can profoundly impact those outcomes. Our partnership with Ochsner Health System and iO enables connections to a large population of patients and researchers in all types of clinical specialties to demonstrate how these innovative technologies can impact healthcare outcomes and value,” said Deborah Kilpatrick, PhD, CEO of Evidation Health.

“We see technology as a ripe opportunity to engage patients in their care and empower them to take a more active role in managing and monitoring their health," said Richard Milani, MD, Ochsner Health System’s chief clinical transformation officer and iO’s chief innovation officer. "Having the data to support this will allow us to further the development of our innovative digital health programs.”

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.